Year-end Sale % OFF 
Abstract
In some randomized clinical trials (RCT), bivalirudin(Biv) -based anticoagulation led to reduced mortality compared with heparin(Hep) -based regimens during PCI. The mortality benefit may be related to lower rates of major bleeding (MB), at the expense of higher rates of early stent thrombosis (ST
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
